Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

PEPTIDES OF BROMODOMAIN TESTIS-SPECIFIC PROTEIN (BRDT)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    April 8, 2021
  • معلومة اضافية
    • Document Number:
      20210101949
    • Appl. No:
      17/031691
    • Application Filed:
      September 24, 2020
    • نبذة مختصرة :
      The present invention relates to novel peptides derived from Bromodomain testis-specific protein (BRDT), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    • Claim:
      1. A polypeptide comprising: (i) the amino acid sequence EMFPKFTEV (SEQ ID NO: 1): (ii) the amino acid sequence RLLDVNNQL (SEQ ID NO: 2) (iii) the amino acid sequence RELEKYVSA (SEQ ID NO: 3) (iv) the amino acid sequence of SEQ ID NOs: 1-3 with the exception of 1, 2 or 3 amino acid substitutions, and/or 1, 2 or 3 amino acid insertions, and/or 1, 2 or 3 amino acid deletions, wherein the polypeptide is capable of forming a complex with a Major Histocompatibility Complex (MHC) molecule.
    • Claim:
      2. The polypeptide of claim 1, wherein the polypeptide consists of from 8 to 16 amino acids.
    • Claim:
      3. The polypeptide of claim 1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NOs 1-3.
    • Claim:
      4. A complex of the polypeptide of claim 1 and a Major Histocompatibility Complex (MHC) molecule.
    • Claim:
      5. The complex of claim 4, wherein the MHC molecule is MHC class I.
    • Claim:
      6. A nucleic acid molecule encoding the polypeptide as defined in claim 1.
    • Claim:
      7. A vector comprising the nucleic acid molecule as defined in claim 6.
    • Claim:
      8. A cell comprising the vector as claimed in claim 7.
    • Claim:
      9. A binding moiety capable of specifically binding the polypeptide of claim 1.
    • Claim:
      10. The binding moiety of claim 9, capable of specifically binding the polypeptide when it is in complex with WIC.
    • Claim:
      11. The binding moiety of claim 10, wherein the binding moiety is a T cell receptor (TCR) or an antibody.
    • Claim:
      12. The binding moiety of claim 11, wherein the binding moiety is a TCR.
    • Claim:
      13. A method of treating or preventing a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a binding moiety as defined in claim 9.
    • Claim:
      14. The method of claim 13, wherein the disease is cancer.
    • Claim:
      15. A pharmaceutical composition comprising a a binding moiety as defined in claim 9 and a pharmaceutically acceptable carrier.
    • Claim:
      16. A method of identifying a binding moiety that binds the complex as defined in claim 4, the method comprising contacting a candidate binding moiety with the complex and determining whether the candidate binding moiety binds the complex.
    • Claim:
      17. The polypeptide of claim 2, wherein the polypeptide consists of from 9 to 12 amino acids.
    • Claim:
      18. The complex of claim 4, wherein the complex further comprises a biotin tag.
    • Claim:
      19. The binding moiety of claim 12, wherein the TCR is on the surface of the cell.
    • Claim:
      20. The binding moiety of claim 11, wherein the binding moiety is an antibody.
    • Current International Class:
      07; 01; 01; 61
    • الرقم المعرف:
      edspap.20210101949